A Patient’s Perspective – Methods to Improve MPN Research by Collecting data and Blood test results from Patients by David Wallace As a PV patient, my treatment has run a wide spectrum during the last 6 years. Starting with phlebotomy only, Hydroxyurea (short time frame), Pegasys (nearing 2 years) and now the “cutting edge combo” […]
Concomitant JAK2 V617F-positive PV and BCR-ABL-positive CML with ruxolitinib and dasatinib
Citation: Blood Cancer Journal (2015) 5, e351; doi:10.1038/bcj.2015.77 Published online 2 October 2015 March 27, 2025 update The combination of ruxolitinib and dasatinib was safe and effective in the treatment of concomitant PV and CML in this patient A Zhou1, E M Knoche1, E K Engle1, D A C Fisher1 and S T Oh1 1Division of Hematology, Washington University School of Medicine, […]
September is Blood Cancer Awareness Month
by David Wallace MPN Awareness for Blood Cancers in September Two quick items for news update: September is Blood Cancer Awareness Month, this is our time to promote MPN – Blood Cancer Awareness….be sure to post one of the many excellent images floating around on your Facebook profile (MPN Research Foundation and LLS have some […]
Imetelstat Active in Myeloproliferative Disorders
Essential thrombocythemia, myelofibrosis respond to telomere targeting Treatment with a drug that targets the chromosome-lengthening enzyme telomerase led to hematologic responses in all treated patients with essential thrombocythemia, a preliminary clinical trial showed. In 16 of 18 cases, patients achieved complete hematologic responses with imetelstat. Additionally, seven of eight patients with Janus kinase 2 (JAK2) […]
